Announcements

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the second half of 2024 in the “Cancer Pathophysiology” Section, which are listed below:

1. “Differential Diagnosis of Pigmented Lesions in the Oral Mucosa: A Clinical Based Overview and Narrative Review”
by Silvio Abati, Giacomo Francesco Sandri, Leonardo Finotello and Elisabetta Polizzi
Cancers 2024, 16(13), 2487; https://doi.org/10.3390/cancers16132487
Available online: https://www.mdpi.com/2072-6694/16/13/2487

2. “The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management”
by Andrea Amaroli, Isabella Panfoli, Matteo Bozzo, Sara Ferrando, Simona Candiani and Silvia Ravera
Cancers 2024, 16(14), 2580; https://doi.org/10.3390/cancers16142580
Available online: https://www.mdpi.com/2072-6694/16/14/2580

3. “Sex- and Age-Associated Differences in Genomic Alterations among Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)”
by ErinMarie O. Kimbrough, Julian A. Marin-Acevedo, Leylah M. Drusbosky, Ariana Mooradian, Yujie Zhao, Rami Manochakian and Yanyan Lou
Cancers 2024, 16(13), 2366; https://doi.org/10.3390/cancers16132366
Available online: https://www.mdpi.com/2072-6694/16/13/2366

4. “Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment”
by Nikolaos Vitorakis, Antonios N. Gargalionis, Kostas A. Papavassiliou, Christos Adamopoulos and Athanasios G. Papavassiliou
Cancers 2024, 16(16), 2876; https://doi.org/10.3390/cancers16162876
Available online: https://www.mdpi.com/2072-6694/16/16/2876

5. “Emerging Role of Hippo-YAP (Yes-Associated Protein)/TAZ (Transcriptional Coactivator with PDZ-Binding Motif) Pathway Dysregulation in Renal Cell Carcinoma Progression”
by Varsha Mondal, Paul J. Higgins and Rohan Samarakoon
Cancers 2024, 16(15), 2758; https://doi.org/10.3390/cancers16152758
Available online: https://www.mdpi.com/2072-6694/16/15/2758

6. “Efficacy of Cisplatin–CXCR4 Antagonist Combination Therapy in Oral Cancer”
by Saori Yoshida, Hotaka Kawai, Yamin Soe, Htoo Shwe Eain, Sho Sanou, Kiyofumi Takabatake, Yohei Takeshita, Miki Hisatomi, Hitoshi Nagatsuka, Junichi Asaumi et al.
Cancers 2024, 16(13), 2326; https://doi.org/10.3390/cancers16132326
Available online: https://www.mdpi.com/2072-6694/16/13/2326

7. “Lung Cancer Subtyping: A Short Review”
by Farzana Siddique, Mohamed Shehata, Mohammed Ghazal, Sohail Contractor and Ayman El-Baz
Cancers 2024, 16(15), 2643; https://doi.org/10.3390/cancers16152643
Available online: https://www.mdpi.com/2072-6694/16/15/2643

8. “Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia”
by Alessandro Costa, Carmelo Gurnari, Emilia Scalzulli, Laura Cicconi, Luca Guarnera, Ida Carmosino, Raffaella Cerretti, Maria Laura Bisegna, Saveria Capria, Clara Minotti et al.
Cancers 2024, 16(18), 3214; https://doi.org/10.3390/cancers16183214
Available online: https://www.mdpi.com/2072-6694/16/18/3214

9. “miRNAs Dysregulated in Human Papillomavirus-Associated Benign Prostatic Lesions and Prostate Cancer”
by Sandra Viridiana Salgado-Hernández, Lucero Martínez-Retamoza, Rodolfo Ocadiz-Delgado, Salvador Pérez-Mora, Gladys Edith Cedeño-Arboleda, María del Consuelo Gómez-García, Patricio Gariglio and David Guillermo Pérez-Ishiwara
Cancers 2025, 17(1), 26; https://doi.org/10.3390/cancers17010026
Available online: https://www.mdpi.com/2072-6694/17/1/26

10. “Profiling Plasma Extracellular Vesicle Metabotypes and miRNAs: An Unobserved Clue for Predicting Relapse in Patients with Early-Stage NSCLC”
by Vivi Bafiti, Eleni Thanou, Sotiris Ouzounis, Athanasios Kotsakis, Vasilis Georgoulias, Evi Lianidou, Theodora Katsila and Athina Markou
Cancers 2024, 16(22), 3729; https://doi.org/10.3390/cancers16223729
Available online: https://www.mdpi.com/2072-6694/16/22/3729

11. “Mutations Matter: Unravelling the Genetic Blueprint of Invasive Lobular Carcinoma for Progression Insights and Treatment Strategies”
by Athanasios Kontogiannis, Eleftheria Karaviti, Dimitra Karaviti, Sophocles Lanitis, Georgia Gomatou, Nikolaos K. Syrigos and Elias Kotteas
Cancers 2024, 16(22), 3826; https://doi.org/10.3390/cancers16223826
Available online: https://www.mdpi.com/2072-6694/16/22/3826

12. “Carcinoembryonic Antigen Expression in Human Tumors: A Tissue Microarray Study on 13,725 Tumors”
by Kristina Jansen, Lara Kornfeld, Maximilian Lennartz, Sebastian Dwertmann Rico, Simon Kind, Viktor Reiswich, Florian Viehweger, Ahmed Abdulwahab Bawahab, Christoph Fraune, Natalia Gorbokon et al.
Cancers 2024, 16(23), 4052; https://doi.org/10.3390/cancers16234052
Available online: https://www.mdpi.com/2072-6694/16/23/4052

13. “Double Heterozygosity for Germline Mutations in Chinese Breast Cancer Patients”
by Ava Kwong, Cecilia Yuen Sze Ho, Chun-Hang Au and Edmond Shiu-Kwan Ma
Cancers 2024, 16(14), 2547; https://doi.org/10.3390/cancers16142547
Available online: https://www.mdpi.com/2072-6694/16/14/2547

14. “Targeting the Leloir Pathway with Galactose-Based Antimetabolites in Glioblastoma”
by Martyn A. Sharpe, Omkar B. Ijare, Sudhir Raghavan, Alexandra M. Baskin, Brianna N. Baskin and David S. Baskin
Cancers 2024, 16(20), 3510; https://doi.org/10.3390/cancers16203510
Available online: https://www.mdpi.com/2072-6694/16/20/3510

15. “Prevalence and Prognostication of CD5+ Mature T-Cell Lymphomas”
by Omar Elghawy, Miao Cao, Jason Xu, Daniel J. Landsburg, Jakub Svoboda, Sunita D. Nasta, Elise A. Chong, Stephen J. Schuster, Colin J. Thomas, Jordan S. Carter et al.
Cancers 2024, 16(19), 3430; https://doi.org/10.3390/cancers16193430
Available online: https://www.mdpi.com/2072-6694/16/19/3430

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

March is designated as Myeloma Awareness Month, with various global activities that highlight and increase awareness of myeloma for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of myeloma, published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information for this field.

The list of relevant papers can be seen below:

1. “Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma”
by Omar Nadeem, Sikander Ailawadhi, Jack Khouri, Louis Williams, Donna Catamero, Kathryn Maples and Jesús Berdeja
Cancers 2024, 16(5), 1023; https://doi.org/10.3390/cancers16051023
Available online: https://www.mdpi.com/2072-6694/16/5/1023

2. “Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma”
by Paola Tacchetti, Simona Barbato, Katia Mancuso, Elena Zamagni and Michele Cavo
Cancers 2024, 16(13), 2337; https://doi.org/10.3390/cancers16132337
Available online: https://www.mdpi.com/2072-6694/16/13/2337

3. “Multiple Myeloma Derived Extracellular Vesicle Uptake by Monocyte Cells Stimulates IL-6 and MMP-9 Secretion and Promotes Cancer Cell Migration and Proliferation”
by Rebecca Sheridan, Kieran Brennan, Despina Bazou, Peter O’Gorman, David Matallanas and Margaret M. Mc Gee
Cancers 2024, 16(5), 1011; https://doi.org/10.3390/cancers16051011
Available online: https://www.mdpi.com/2072-6694/16/5/1011

4. “Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma”
by Basudev Chowdhury, Swati Garg, Wei Ni, Martin Sattler, Dana Sanchez, Chengcheng Meng, Taisei Akatsu, Richard Stone, William Forrester, Edmund Harrington et al.
Cancers 2024, 16(7), 1319; https://doi.org/10.3390/cancers16071319
Available online: https://www.mdpi.com/2072-6694/16/7/1319

5. “Role of Non-Coding RNAs in Diagnosis, Prediction and Prognosis of Multiple Myeloma”
by Maciej Dubaj, Karol Bigosiński, Aleksandra Dembowska, Radosław Mlak, Aneta Szudy-Szczyrek, Teresa Małecka-Massalska and Iwona Homa-Mlak
Cancers 2024, 16(5), 1033; https://doi.org/10.3390/cancers16051033
Available online: https://www.mdpi.com/2072-6694/16/5/1033

6. “Functional Investigation of IGF1R Mutations in Multiple Myeloma”
by Sofia Catalina Heredia-Guerrero, Marietheres Evers, Sarah Keppler, Marlene Schwarzfischer, Viktoria Fuhr, Hilka Rauert-Wunderlich, Anne Krügl, Theodora Nedeva, Tina Grieb, Julia Pickert
Cancers 2024, 16(11), 2139; https://doi.org/10.3390/cancers16112139
Available online: https://www.mdpi.com/2072-6694/16/11/2139

7. “Utilizing 3D Models to Unravel the Dynamics of Myeloma Plasma Cells’ Escape from the Bone Marrow Microenvironment”
by Stefaan W. Verbruggen, Ciara L. Freeman and Fiona E. Freeman
Cancers 2024, 16(5), 889; https://doi.org/10.3390/cancers16050889
Available online: https://www.mdpi.com/2072-6694/16/5/889

8. “The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management”
by Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia and Massimo Offidani
Cancers 2024, 16(12), 2263; https://doi.org/10.3390/cancers16122263
Available online: https://www.mdpi.com/2072-6694/16/12/2263

9. “Novel Insights into the Initiation, Evolution, and Progression of Multiple Myeloma by Multi-Omics Investigation”
by Lixin Gong, Lugui Qiu and Mu Hao
Cancers 2024, 16(3), 498; https://doi.org/10.3390/cancers16030498
Available online: https://www.mdpi.com/2072-6694/16/3/498

10. “Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery”
by Julian Mehl, Dilara Akhoundova, Ulrike Bacher, Barbara Jeker, Gaëlle Rhyner Agocs, Axel Ruefer, Susanne Soltermann, Martin Soekler, Annette Winkler, Michael Daskalakis et al.
Cancers 2024, 16(10), 1854; https://doi.org/10.3390/cancers16101854
Available online: https://www.mdpi.com/2072-6694/16/10/1854

11. “Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma Patients”
by Omar S. Al-Odat, Emily Nelson, Tulin Budak-Alpdogan, Subash C. Jonnalagadda, Dhimant Desai and Manoj K. Pandey
Cancers 2024, 16(13), 2381; https://doi.org/10.3390/cancers16132381
Available online: https://www.mdpi.com/2072-6694/16/13/2381

12. “A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation”
by Wancheng Guo, Christopher Strouse, David Mery, Eric R. Siegel, Manit N. Munshi, Timothy Cody Ashby, Yan Cheng, Fumou Sun, Visanu Wanchai, Zijun Zhang et al.
Cancers 2024, 16(6), 1116; https://doi.org/10.3390/cancers16061116
Available online: https://www.mdpi.com/2072-6694/16/6/1116

13. “Effects on the Physical Functioning of Two Exercise Interventions in Patients with Multiple Myeloma: A Pilot Feasibility Study”
by Jens Hillengass, Michaela Hillengass, Janine M. Joseph, Kristopher Attwood, Rikki Cannioto, Hillary Jacobson, Carolyn Miller, Bryan Wittmeyer and Kirsten Moysich
Cancers 2024, 16(9), 1774; https://doi.org/10.3390/cancers16091774
Available online: https://www.mdpi.com/2072-6694/16/9/1774

14. “IL1B Polymorphism (rs1143634) and IL-1β Plasma Concentration as Predictors of Nutritional Disorders and Prognostic Factors in Multiple Myeloma Patients”
by Marcin Mazurek, Aneta Szudy-Szczyrek, Iwona Homa-Mlak, Marek Hus, Teresa Małecka-Massalska and Radosław Mlak
Cancers 2024, 16(7), 1263; https://doi.org/10.3390/cancers16071263
Available online: https://www.mdpi.com/2072-6694/16/7/1263

You are welcome to submit relevant papers to the journal Cancers.

Cancers Editorial Office

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the second half of 2024 in the “Cancer Causes, Screening and Diagnosis” Section, which are listed below:

1. “Management for Cervical Cancer Patients: A Comparison of the Guidelines from the International Scientific Societies (ESGO-NCCN-ASCO-AIOM-FIGO-BGCS-SEOM-ESMO-JSGO)”
by Stefano Restaino, Giulia Pellecchia, Martina Arcieri, Giorgio Bogani, Cristina Taliento, Pantaleo Greco, Lorenza Driul, Vito Chiantera, Alfredo Ercoli, Francesco Fanfani et al.
Cancers 2024, 16(14), 2541; https://doi.org/10.3390/cancers16142541
Available online: https://www.mdpi.com/2072-6694/16/14/2541

2. “Non-Invasive Markers for the Detection of Gastric Precancerous Conditions”
by Marcin Romańczyk, Malgorzata Osmola, Alexander Link, Amaury Druet, Caroline Hémont, Jerome Martin, Nicolas Chapelle and Tamara Matysiak-Budnik
Cancers 2024, 16(12), 2254; https://doi.org/10.3390/cancers16122254
Available online: https://www.mdpi.com/2072-6694/16/12/2254

3. “Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings”
by Ilaria Attili, Carla Corvaja, Gianluca Spitaleri, Pamela Trillo Aliaga, Ester Del Signore, Antonio Passaro and Filippo de Marinis
Cancers 2024, 16(14), 2589; https://doi.org/10.3390/cancers16142589
Available online: https://www.mdpi.com/2072-6694/16/14/2589

4. “The “Road” to Malignant Transformation from Endometriosis to Endometriosis-Associated Ovarian Cancers (EAOCs): An mTOR-Centred Review”
by Radwa Hablase, Ioannis Kyrou, Harpal Randeva, Emmanouil Karteris and Jayanta Chatterjee
Cancers 2024, 16(11), 2160; https://doi.org/10.3390/cancers16112160
Available online: https://www.mdpi.com/2072-6694/16/11/2160

5. “Preliminary Experience in Ultra-High Frequency Ultrasound Assessment of Cutaneous Primary Lymphomas: An Innovative Classification”
by Anna Russo, Vittorio Patanè, Federico Gagliardi, Fabrizio Urraro, Andrea Ronchi, Paola Vitiello, Antonello Sica, Giuseppe Argenziano, Valerio Nardone and Alfonso Reginelli
Cancers 2024, 16(13), 2456; https://doi.org/10.3390/cancers16132456
Available online: https://www.mdpi.com/2072-6694/16/13/2456

6. “Enhancing Early Lung Cancer Diagnosis: Predicting Lung Nodule Progression in Follow-Up Low-Dose CT Scan with Deep Generative Model”
by Yifan Wang, Chuan Zhou, Lei Ying, Heang-Ping Chan, Elizabeth Lee, Aamer Chughtai, Lubomir M. Hadjiiski and Ella A. Kazerooni
Cancers 2024, 16(12), 2229; https://doi.org/10.3390/cancers16122229
Available online: https://www.mdpi.com/2072-6694/16/12/2229

7. “Revisiting Querleu–Morrow Radical Hysterectomy: How to Apply the Anatomy of Parametrium and Pelvic Autonomic Nerves to Cervical Cancer Surgery?”
by Stoyan Kostov, Yavor Kornovski, Rafał Watrowski, Angel Yordanov, Stanislav Slavchev, Yonka Ivanova, Hakan Yalcin, Ivan Ivanov and Ilker Selcuk
Cancers 2024, 16(15), 2729; https://doi.org/10.3390/cancers16152729
Available online: https://www.mdpi.com/2072-6694/16/15/2729

8. “Amplified Cell Cycle Genes Identified in High-Grade Serous Ovarian Cancer”
by Karthik Balakrishnan, Yuanhong Chen and Jixin Dong
Cancers 2024, 16(16), 2783; https://doi.org/10.3390/cancers16162783
Available online: https://www.mdpi.com/2072-6694/16/16/2783

9. “Prevalence of Sarcopenia Determined by Computed Tomography in Pancreatic Cancer: A Systematic Review and Meta-Analysis of Observational Studies”
by Antonio Jesús Láinez Ramos-Bossini, Antonio Gámez Martínez, David Luengo Gómez, Francisco Valverde-López, Consolación Melguizo and José Prados
Cancers 2024, 16(19), 3356; https://doi.org/10.3390/cancers16193356
Available online: https://www.mdpi.com/2072-6694/16/19/3356

10. “Prognostic Relevance of Preoperative Immune, Inflammatory, and Nutritional Biomarkers in Patients Undergoing Gastrectomy for Resectable Gastric Adenocarcinoma: An Observational Multicentre Study”
by Jaume Tur-Martínez, Joaquín Rodríguez-Santiago, Javier Osorio, Mònica Miró, Concepción Yarnoz, Mariona Jofra, Georgina Ferret, Helena Salvador-Roses, Sonia Fernández-Ananín, Arantxa Clavell et al.
Cancers 2024, 16(12), 2188; https://doi.org/10.3390/cancers16122188
Available online: https://www.mdpi.com/2072-6694/16/12/2188

11. “Wearable Devices in Colorectal Surgery: A Scoping Review”
by Konstantinos Kavallieros, Lampros Karakozis, Romilly Hayward, Emmanuel Giannas, Lucio Selvaggi and Christos Kontovounisios
Cancers 2024, 16(13), 2303; https://doi.org/10.3390/cancers16132303
Available online: https://www.mdpi.com/2072-6694/16/13/2303

12. “Locally Advanced Cervical Cancer: Neoadjuvant Treatment versus Standard Radio-Chemotherapy—An Updated Meta-Analysis”
by Carlo Ronsini, Maria Cristina Solazzo, Eleonora Braca, Giada Andreoli, Maria Giovanna Vastarella, Stefano Cianci, Vito Andrea Capozzi, Marco Torella, Luigi Cobellis and Pasquale De Franciscis
Cancers 2024, 16(14), 2542; https://doi.org/10.3390/cancers16142542
Available online: https://www.mdpi.com/2072-6694/16/14/2542

13. “WFUMB Review Paper. Incidental Findings in Otherwise Healthy Subjects, How to Manage: Liver ”
by Roxana Șirli, Alina Popescu, Christian Jenssen, Kathleen Möller, Adrian Lim, Yi Dong, Ioan Sporea, Dieter Nürnberg, Marieke Petry and Christoph F. Dietrich
Cancers 2024, 16(16), 2908; https://doi.org/10.3390/cancers16162908
Available online: https://www.mdpi.com/2072-6694/16/16/2908

14. “The Role of Radiomics in the Prediction of Clinically Significant Prostate Cancer in the PI-RADS v2 and v2.1 Era: A Systematic Review”
by Andreu Antolin, Nuria Roson, Richard Mast, Javier Arce, Ramon Almodovar, Roger Cortada, Almudena Maceda, Manuel Escobar, Enrique Trilla and Juan Morote
Cancers 2024, 16(17), 2951; https://doi.org/10.3390/cancers16172951
Available online: https://www.mdpi.com/2072-6694/16/17/2951

15. “Leucocyte Telomere Length and Lung Cancer Risk: A Systematic Review and Meta-Analysis of Prospective Studies”
by Roberto Fabiani, Manuela Chiavarini, Patrizia Rosignoli and Irene Giacchetta
Cancers 2024, 16(18), 3218; https://doi.org/10.3390/cancers16183218
Available online: https://www.mdpi.com/2072-6694/16/18/3218

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

We are pleased to announce that nine new scholars have been appointed as Editorial Board Members (EBMs) of Cancers (ISSN: 2072-6694), joining in January 2025. We wish our new members success in both their research and their efforts to develop the journal.

Further details about the Editorial Board of Cancers can be found by clicking the following link: https://www.mdpi.com/journal/cancers/editors.

Cancers is recruiting scholars from around the world to join our Editorial Board. To apply for membership, recommend potential candidates, or request further information, please contact the Cancers Editorial Office and provide the following files:

• A full academic CV;
• A short cover letter that details your interest in the position.

March is designated as Kidney Cancer Awareness Month, with various global activities that highlight and increase awareness of kidney cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of kidney cancer, published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information for this field.

The list of relevant papers is provided below:

“Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study”
by Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun and Jinsoo Chung
Cancers 2024, 16(18), 3161; https://doi.org/10.3390/cancers16183161
Available online: https://www.mdpi.com/2072-6694/16/18/3161

“Accumulation of 3-Monochloro-Propanediol Esters in Kidney Tissues of Patients with Human Renal Cell Carcinoma”
by Che-Yuan Hu, Yu-An Wang, Kai-Wei Liao, Hung-Tsung Wu, Chien-Hui Ou, Choon Hui Tan and Wei-Ju Lee
Cancers 2024, 16(19), 3313; https://doi.org/10.3390/cancers16193313
Available online: https://www.mdpi.com/2072-6694/16/19/3313

“The Current State of the Diagnoses and Treatments for Clear Cell Renal Cell Carcinoma”
by Anthony E. Quinn, Scott D. Bell, Austin J. Marrah, Mark R. Wakefield and Yujiang Fang
Cancers 2024, 16(23), 4034; https://doi.org/10.3390/cancers16234034
Available online: https://www.mdpi.com/2072-6694/16/23/4034

“The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma”
by Tsukasa Narukawa, Shusuke Yasuda, Mano Horinaka, Keiko Taniguchi, Takahiro Tsujikawa, Mie Morita, Osamu Ukimura and Toshiyuki Sakai
Cancers 2024, 16(23), 4058; https://doi.org/10.3390/cancers16234058
Available online: https://www.mdpi.com/2072-6694/16/23/4058

“Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors”
by Takuto Shimizu, Makito Miyake, Nobutaka Nishimura, Takanori Yoshida, Yoshitaka Itami, Akira Tachibana, Chihiro Omori, Yuki Oda, Mikiko Kohashi, Mitsuru Tomizawa et al.
Cancers 2024, 16(4), 841; https://doi.org/10.3390/cancers16040841
Available online: https://www.mdpi.com/2072-6694/16/4/841

“Emerging Role of Hippo-YAP (Yes-Associated Protein)/TAZ (Transcriptional Coactivator with PDZ-Binding Motif) Pathway Dysregulation in Renal Cell Carcinoma Progression”
by Varsha Mondal, Paul J. Higgins and Rohan Samarakoon
Cancers 2024, 16(15), 2758; https://doi.org/10.3390/cancers16152758
Available online: https://www.mdpi.com/2072-6694/16/15/2758

“Non-Metastatic Clear Cell Renal Cell Carcinoma Immune Cell Infiltration Heterogeneity and Prognostic Ability in Patients Following Surgery”
by Daniel D. Shapiro, Taja Lozar, Lingxin Cheng, Elliot Xie, Israa Laklouk, Moon Hee Lee, Wei Huang, David F. Jarrard, Glenn O. Allen, Rong Hu et al.
Cancers 2024, 16(3), 478; https://doi.org/10.3390/cancers16030478
Available online: https://www.mdpi.com/2072-6694/16/3/478

“The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)—What Future Prospects Are There for Its Use in Clinical Practice?”
by Martina Panebianco, Chiara Ciccarese, Alessandro Strusi, Viria Beccia, Carmine Carbone, Antonio Agostini, Geny Piro, Giampaolo Tortora and Roberto Iacovelli
Cancers 2024, 16(3), 490; https://doi.org/10.3390/cancers16030490
Available online: https://www.mdpi.com/2072-6694/16/3/490

“Targeting NPC1 in Renal Cell Carcinoma”
by Rushaniya Fazliyeva, Peter Makhov, Robert G. Uzzo and Vladimir M. Kolenko
Cancers 2024, 16(3), 517; https://doi.org/10.3390/cancers16030517
Available online: https://www.mdpi.com/2072-6694/16/3/517

“Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival”
by Andrea Ossato, Lorenzo Gasperoni, Luna Del Bono, Andrea Messori and Vera Damuzzo
Cancers 2024, 16(3), 557; https://doi.org/10.3390/cancers16030557
Available online: https://www.mdpi.com/2072-6694/16/3/557

“Ex Vivo Vascular Imaging and Perfusion Studies of Normal Kidney and Tumor Vasculature”
by Ragnar Hultborn, Lilian Weiss, Egil Tveit, Stefan Lange, Eva Jennische, Malin C. Erlandsson and Martin E. Johansson
Cancers 2024, 16(10), 1939; https://doi.org/10.3390/cancers16101939
Available online: https://www.mdpi.com/2072-6694/16/10/1939

“Prognostic Significance of Elevated UCHL1, SNRNP200, and PAK4 Expression in High-Grade Clear Cell Renal Cell Carcinoma: Insights from LC-MS/MS Analysis and Immunohistochemical Validation”
by Michał Kasperczak, Gabriel Bromiński, Iga Kołodziejczak-Guglas, Andrzej Antczak and Maciej Wiznerowicz
Cancers 2024, 16(16), 2844; https://doi.org/10.3390/cancers16162844
Available online: https://www.mdpi.com/2072-6694/16/16/2844

“The Added Value of Controlling Nutritional Status (Conut) Score for Preoperative Counselling on Significant Early Loss of Renal Function After Radical Nephrectomy for Renal Cell Carcinoma”
by Matteo Boltri, Fabio Traunero, Luca Ongaro, Francesca Migliozzi, Fabio Vianello, Oliviero Lenardon, Francesco Visalli, Lorenzo Buttazzi, Daniele Maruzzi, Carlo Trombetta et al.
Cancers 2024, 16(20), 3519; https://doi.org/10.3390/cancers16203519
Available online: https://www.mdpi.com/2072-6694/16/20/3519

“Financial Toxicity in Japanese Patients with Metastatic Renal Cell Carcinoma: A Cross-Sectional Study”
by Go Kimura, Yasuhisa Fujii, Kazunori Honda, Takahiro Osawa, Yosuke Uchitomi, Miki Kondo, Ariko Otani, Tetsuya Wako, Daisuke Kawai, Yoshihide Mitsuda et al.
Cancers 2024, 16(10), 1904; https://doi.org/10.3390/cancers16101904
Available online: https://www.mdpi.com/2072-6694/16/10/1904

“Type Disparity in Sodium–Glucose Cotransporter-2 Inhibitors in Incidences of Renal Cell Carcinoma: A Propensity-Score-Matched Cohort Study”
by Tsung-Kun Lin, Wei-Yao Wang, Tsung-Yuan Yang and Gwo-Ping Jong
Cancers 2024, 16(11), 2145; https://doi.org/10.3390/cancers16112145
Available online: https://www.mdpi.com/2072-6694/16/11/2145

You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

MDPI is pleased to share a significant milestone in its mission to advance scholarly research and promote the dissemination of knowledge—300+ MDPI journals are now indexed in Web of Science (WoS). This milestone highlights the global recognition, interdisciplinary impact and enhanced visibility of our journals. It also reflects our adherence to rigorous editorial standards, scientific integrity, and our mission to foster open scientific exchange in all forms, across all disciplines. 

To explore the full list of our journals indexed in WoS, please visit https://www.mdpi.com/about/journals/wos. Beyond expanding the coverage of our publications in the leading academic databases, we are dedicated to ensuring that our journals are included in as many scope-specific databases as possible. This increases the visibility of our authors’ work and extends the reach of their significant data. 

This milestone would not have been possible without the efforts and expertise of our academic editors, reviewers and authors. Their commitment and collaboration have been instrumental in creating an inclusive, accessible, and impactful publishing platform. We also extend our gratitude to the global research community for their trust as we continue to break new ground in academic publishing. This milestone is not just a celebration of MDPI’s progress but also recognition of the collective strides made by researchers worldwide. 

As we celebrate this remarkable accomplishment, MDPI remains steadfast in its commitment to open access publishing and ensuring that high-quality research reaches and inspires a global audience.

MDPI, a pioneer in scholarly open access publishing, and the Lee Kong Chian School of Medicine (LKCMedicine), Singapore, proudly announce the successful conclusion of the first edition the MDPI Early Career Researcher Awards. The awards, which recognize outstanding contributions to medical and biomedical research, were presented to six exceptional researchers during an awards ceremony held at LKCMedicine HQ Building on 28 November 2024.

Honoring Excellence in Research

The awards recognize exceptional postdoctoral researchers and Ph.D. students who have demonstrated outstanding originality, innovation, and impact in their respective fields. We are honored to announce the winners of the 2024 edition:

Early Career Researcher (Postdoc) Award:

• Dr. Theresia Handayani Mina, “Adiposity and Metabolic Health in Asian Populations: An Epidemiological Study Using Dual-Energy X-Ray Absorptiometry in Singapore”;
• Dr. Erfan Rezvani Ghomi, “Wound Healing Improvement by Novel Aligned Antimicrobial Nanofibrous 3D Scaffolds”;
• Dr. Yadollah Ranjbar Slamloo, “Functional Alterations of The Prefrontal Circuit Underlying Cognitive Aging in Mice”.

Early Career Researcher (Ph.D.) Award:

• Pritisha Rozario, “Mechanistic Basis for Potassium Efflux-Driven Activation of the Human NLRP1 Inflammasome”;

• Michelle Law Cheok Yien, “Chikungunya Virus Nonstructural Protein 1 is a Versatile RNA Capping and Decapping Enzyme”;
• Yin Ruoyu, “The Use of Digital Mental Health and Wellbeing Tools in Older Adults: A Mixed Method Study”.

Our collaboration highlights a shared commitment to recognizing exceptional talent and research within the academic community, addressing today’s healthcare challenges, and inspiring continued innovation.

Looking Ahead to 2025

Building on the success of the first edition, MDPI and LKCMedicine are excited to announce that the 2025 MDPI Early Researcher Awards will continue to celebrate excellence and innovation in medical research. The next edition promises to expand its scope, introducing new categories and providing even greater recognition for impactful research.

Further details on the 2025 awards, including nomination criteria and timelines, will be shared in the coming months. We remain committed to fostering a culture of research excellence and collaboration within the global scientific community.

We are pleased to announce that seven new scholars have been appointed as Editorial Board Members (EBMs) of Cancers (ISSN: 2072-6694), joining in December 2024. We wish our new members success in both their research and their efforts to develop the journal.

Name: Prof. Dr. Franz Rödel
Affiliation: Department of Radiotherapy and Oncology, Goethe University Frankfurt am Main, 60590 Frankfurt am Main, Germany
Interests: translational research; biomarker development; cancer radioimmunotherapy; low-dose anti-inflammatory radiation therapy; tumor microenviroment; survivin; molecular targeting

Name: Prof. Dr. Junya Fujimoto
Affiliation: Department of Translational Molecular Pathology (Affiliated Department in Hospital), Clinical Research Center in Hiroshima, Hiroshima University Hospital, Hiroshima 734-8551, Japan
Interests: molecular pathology; lung cancer; pre-malignant cancer; intra-tumor heterogeneity; system biorepository for multimodal integration; translational research

Name: Dr. Gianluca Tomasello
Affiliation: Oncology Division, ASST Crema, Ospedale Maggiore di Crema, Largo U. Dossena 2, 26013 Crema, CR, Italy
Interests: breast cancer; gastrointestinal cancers; clinical trials

Name: Prof. Dr. Matteo Donadon
Affiliations: ¹ Department of Health Sciences, University of Piemonte Orientale, 28100 Novara, Italy; ² Division of General Surgery, University Maggiore Hospital della Carità, 28100, Novara, Italy
Interests: cholangiocarcinoma; Klatskin tumor; colorectal liver metastases; neuroendocrine tumors; hepatocellular carcinoma; hepatic resection; hepatectomy; liver resection; liver surgery; parenchymal-sparing liver surgery; intraoperative ultrasound; liver-specific magnetic resonance imaging; trans-arterial therapy; liver function; FibroScan; pancreatic tumor; pancreatic resection; laparoscopic surgery; robotic surgery

Name: Dr. Evangelos Kolettas
Affiliations: ¹ Laboratory of Biology, School of Medicine, Faculty of Health Sciences, Institute of Biosciences, University Research Centre, University of Ioannina, 451 10 Ioannina, Greece; ² Molecular Cancer Biology & Senescence Labortaory, Biomedical Research Institute (BRI), Foundation for Research and Technology (FORTH), Ioannina, Greece
Interests: cancer; senescence; DNA damage; inflammation; epithelial-to-mesenchymal cell transition; cell signalling; NF-kappaB; transcriptional regulation; epigenetics; miRNA

 Name: Dr. Gianluca Tenore
Affiliation: Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, 00161 Rome, Italy
Interests: oral medicine; oral pathology; oral cancer; oral surgery; laser in dentistry

Name: Dr. Giovanni Luca Ceresoli
Affiliation: Department of Oncology, Thoracic and Urologic Oncology Unit, Cliniche Humanitas Gavazzeni, via Gavazzeni 21, 24125 Bergamo, Italy
Interests: malignant pleural mesothelioma (main); lung cancer; prostate cancer; renal cancer

Further details about the Editorial Board of Cancers can be found by clicking the following link: https://www.mdpi.com/journal/cancers/editors.

Cancers is recruiting scholars from around the world to join our Editorial Board. To apply for membership, recommend potential candidates, or request further information, please contact the Cancers Editorial Office (cancers@mdpi.com) and provide the following files:

• A full academic CV;
• A short cover letter detailing your interest in the position.

We are delighted to share some highly viewed papers on cancer drug development that were published in Cancers (ISSN: 2072-6694) in 2024. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will interest you.

The list of relevant papers can be seen below:

“Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs”
by Virginia Metrangolo and Lars H. Engelholm
Cancers 2024, 16(2), 447; https://doi.org/10.3390/cancers16020447
Available online: https://www.mdpi.com/2072-6694/16/2/447

“Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer”
by Xin Gu and Tamara Minko
Cancers 2024, 16(8), 1589; https://doi.org/10.3390/cancers16081589
Available online: https://www.mdpi.com/2072-6694/16/8/1589

“Peptide Therapeutics: Unveiling the Potential against Cancer—A Journey through 1989”
by Othman Al Musaimi
Cancers 2024, 16(5), 1032; https://doi.org/10.3390/cancers16051032
Available online: https://www.mdpi.com/2072-6694/16/5/1032

“Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review”
by Nilesh Kumar Sharma, Anjali Bahot, Gopinath Sekar, Mahima Bansode, Kratika Khunteta, Priyanka Vijay Sonar, Ameya Hebale, Vaishnavi Salokhe and Birandra Kumar Sinha
Cancers 2024, 16(4), 680; https://doi.org/10.3390/cancers16040680
Available online: https://www.mdpi.com/2072-6694/16/4/680

“Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma”
by Ali Al Sbihi, Maryam Alasfour and Georgios Pongas
Cancers 2024, 16(4), 827; https://doi.org/10.3390/cancers16040827
Available online: https://www.mdpi.com/2072-6694/16/4/827

“DDX3X and Stress Granules: Emerging Players in Cancer and Drug Resistance”
by Han Zhang, Paula M. Mañán-Mejías, Hannah N. Miles, Andrea A. Putnam, Leonard R. MacGillivray and William A. Ricke
Cancers 2024, 16(6), 1131; https://doi.org/10.3390/cancers16061131
Available online: https://www.mdpi.com/2072-6694/16/6/1131

Special Issues:

You are invited to view and submit relevant papers to the journal Cancers at the following link: https://www.mdpi.com/journal/cancers.

We are delighted to share some highly viewed papers on cancer epidemiology and prevention that were published in Cancers (ISSN: 2072-6694) in 2024. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will interest you.

The list of relevant papers can be seen below:

“Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape”
by Emily Kinsey and Hannah M. Lee
Cancers 2024, 16(3), 666; https://doi.org/10.3390/cancers16030666
Available online: https://www.mdpi.com/2072-6694/16/3/666

“Prognosis and Treatment of Gastric Cancer: A 2024 Update”
by Claudia Burz, Vlad Pop, Ciprian Silaghi, Iulia Lupan and Gabriel Samasca
Cancers 2024, 16(9), 1708; https://doi.org/10.3390/cancers16091708
Available online: https://www.mdpi.com/2072-6694/16/9/1708

“Interplay of Ferroptosis and Cuproptosis in Cancer: Dissecting Metal-Driven Mechanisms for Therapeutic Potentials”
by Jinjiang Wang, Jiaxi Li, Jiao Liu, Kit-Ying Chan, Ho-Sze Lee, Kenneth Nansheng Lin, Chi-Chiu Wang and Tat-San Lau
Cancers 2024, 16(3), 512; https://doi.org/10.3390/cancers16030512
Available online: https://www.mdpi.com/2072-6694/16/3/512

“Outcomes and Techniques of Robotic-Assisted Partial Nephrectomy (RAPN) for Renal Hilar Masses: A Comprehensive Systematic Review”
by Savio Domenico Pandolfo, Zhenjie Wu, Riccardo Campi, Riccardo Bertolo, Daniele Amparore, Andrea Mari, Paolo Verze, Celeste Manfredi, Antonio Franco, Francesco Ditonno et al.
Cancers 2024, 16(4), 693; https://doi.org/10.3390/cancers16040693
Available online: https://www.mdpi.com/2072-6694/16/4/693

“Targeted Therapeutic Strategies for the Treatment of Cancer”
by Benjamin Victoir, Cécile Croix, Fabrice Gouilleux and Gildas Prié
Cancers 2024, 16(2), 461; https://doi.org/10.3390/cancers16020461
Available online: https://www.mdpi.com/2072-6694/16/2/461

“Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions”
by Rohan Kalyan Rej, Joyeeta Roy and Srinivasa Rao Allu
Cancers 2024, 16(3), 552; https://doi.org/10.3390/cancers16030552
Available online: https://www.mdpi.com/2072-6694/16/3/552

Special Issues:

“Novel Combinatorial Approaches for Immunotherapy and Targeted Therapies in Cancer” Guest Editors: Dr. Claudia De Lorenzo and Dr. Laura Cerchia Submission deadline: 31 March 2025	“Novel Therapeutic Strategies in Salivary Gland Tumor” Guest Editors: Dr. Giovanni Salzano, Dr. Arianna Di Stadio and Dr. Luigi Angelo Vaira Submission deadline: 30 April 2025
“Current Advances in Management of Neuroendocrine Neoplasms” Guest Editors: Dr. Ashley Kieran Clift and Prof. Dr. Andrea Frilling Submission deadline: 30 May 2025	“Pulmonary Nodule and Lung Cancer: Diagnosis and Clinical Treatment” Guest Editor: Dr. Morena Fasano Submission deadline: 20 June 2025

You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.

Cancers Editorial Office